The nuclear receptor peroxisome proliferator-activator gamma (PPARγ) is a useful therapeutic target for obesity and diabetes, but its role in protecting β-cell function and viability is unclear. Methods: To identify the potential functions of PPARγ in β-cells, we treated mouse insulinoma 6 (MIN6) cells with the PPARγ agonist pioglitazone in conditions of lipotoxicity, endoplasmic reticulum (ER) stress, and inflammation. Results: Palmitate-treated cells incubated with pioglitazone exhibited significant improvements in glucose-stimulated insulin secretion and the repression of apoptosis, as shown by decreased caspase-3 cleavage and poly (adenosine diphosphate [ADP]-ribose) polymerase activity. Pioglitazone also reversed the palmitate-induced expression of inflammatory cytokines (tumor necrosis factor α, interleukin 6 [IL-6], and IL-1β) and ER stress markers (phosphor-eukaryotic translation initiation factor 2α, glucose-regulated protein 78 [GRP78], cleaved-activating transcription factor 6 [ATF6], and C/EBP homologous protein [CHOP]), and pioglitazone significantly attenuated inflammation and ER stress in lipopolysaccharide-or tunicamycin-treated MIN6 cells. The protective effect of pioglitazone was also tested in pancreatic islets from high-fat-fed KK-Ay mice administered 0.02% (wt/wt) pioglitazone or vehicle for 6 weeks. Pioglitazone remarkably reduced the expression of ATF6α, GRP78, and monocyte chemoattractant protein-1, prevented α-cell infiltration into the pancreatic islets, and upregulated glucose transporter 2 (Glut2) expression in β-cells. Moreover, the preservation of β-cells by pioglitazone was accompanied by a significant reduction of blood glucose levels. Conclusion: Altogether, these results support the proposal that PPARγ agonists not only suppress insulin resistance, but also prevent β-cell impairment via protection against ER stress and inflammation. The activation of PPARγ might be a new therapeutic approach for improving β-cell survival and insulin secretion in patients with diabetes mellitus.
INTRODUCTION
Chronic exposure to high levels of glucose and non-esterified fatty acids results in pancreatic β-cell dysfunction and death, thereby leading to the onset of type 2 diabetes [1] . Thiazolidinediones (TZDs) are specific agonists of peroxisome proliferatoractivator gamma (PPARγ), a nuclear transcription factor, and several TZDs are prescribed throughout the world to treat type 2 diabetes. The main goal of TZD therapy is to improve the insulin sensitivity of peripheral tissues, but many studies in human and animal models have reported that these agents could protect pancreatic β-cells [2, 3] . PPARγ agonists were found to protect the viability and function of β-cells against human islet amyloid polypeptide (IAPP)-induced toxicity [3] . Moreover, PPARγ expression has been detected in the pancreatic islet, and treatment with a PPARγ agonist or overexpression of PPARG improved glucose-stimulated insulin secretion, with an increased expression of genes involved in β-cell function, including glucose transporter 2 (GLUT2), insulin receptor substrate 2 (IRS2), and pancreatic duodenal homeobox 1 (PDX1) [4] .
In type 2 diabetes and/or obesity, numerous etiological factors lead to dysfunction and apoptosis of pancreatic β-cells, such as inflammation, oxidative stress, and endoplasmic reticulum (ER) stress [5] . Several clinical studies have suggested that anti-inflammatory therapy in patients with type 2 diabetes may improve hyperglycemia and insulin secretion by β-cells [6, 7] , and inflammation is known to be a pivotal pathway in the pathogenesis of various forms of cellular dysfunction and apoptosis. Pancreatic β-cells are exposed to circulating cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), and interferon gamma, which inhibit insulin secretion by interrupting calcium flow. Moreover, TNF-α induces β-cell death via the expression and cellular deposition of IAPP [7] , and increased cellular deposition of IAPP causes β-cell inflammation [8] [9] [10] . The inflammation of β-cells can also be caused by lipotoxicity, which is induced by the irregular increase of free fatty acids, including palmitic acid. This causes oxidative stress and jun N-terminal kinase (JNK) activation [10] , further increases the expression of TNF-α, IL-1β, IL-6, and IL-8, and activates nuclear factor-kappa B (NF-κB) in pancreatic β-cells, leading to β-cell dysfunction and apoptosis [11] .
Although ER stress is linked to cellular damage in all tissues involved in diabetes [12] , it is a factor to which insulin-releasing β-cells are particularly susceptible. Abnormal expansion of the ER was observed in β-cells from patients with type 2 diabetes, and ER stress markers were increased in islets from db/db mice and β-cells of type 2 diabetes patients [13, 14] . These studies suggest that ER stress is a strong etiological factor inducing β-cell impairment. Exposure to high levels of glucose and lipids is known to induce the overproduction of insulin, which leads to β-cell dysfunction and apoptosis through ER stress. In the early stages of ER stress, the unfolded protein response (UPR) is activated to maintain the ER function through an increase in UPR proteins, such as glucose-regulated protein 78 (GRP78), phosphor-eukaryotic translation initiation factor 2-α (p-eIF2α), and activating transcription factor 6 (ATF6); however, chronic activation of UPR increases the expression of C/EBP homologous protein (CHOP) and results in cell death. CHOP is a transcriptional regulator that stimulates cell death by downregulating the anti-apoptotic protein Bcl-2 and upregulating cellular reactive oxygen species and ER oxidoreductase 1, leading to hyperoxidizing conditions in the ER [15] .
Although growing evidence suggests that the activation of PPARγ preserves pancreatic islets, the mechanism through which PPARγ acts to regulate molecular abnormalities is poorly understood. In the present study, therefore, we examined the effects of a PPARγ agonist on the regulation of glucolipotoxicityinduced pathophysiological events, focusing on the inflammatory response and ER stress in pancreatic β-cells.
METHODS

Cell culture and treatment
Mouse insulinoma 6 (MIN6) cell lines (passages 15 to 25) were cultured at 37°C in a humidified incubator with 5% CO2 in Dulbecco's Modified Eagle's medium (DMEM) containing 4.5 g/L glucose supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin, 50 µg/mL streptomycin, and 50 µM 2-mercaptoethanol (all from Life Technologies, Paisley, UK). At 50% to 70% confluence, the cells were incubated with or without 10 µM pioglitazone (Takara Pharmaceuticals, Kusatsu, Japan) and/or 0.5 mM palmitic acid (R&D Systems Inc., Minneapolis, MN, USA) in different glucose concentrations (1 or 4.5 g/L) for 48 hours. A group of cells was treated with 10 µg/mL lipopolysaccharide (LPS) and/or 10 µM pioglitazone, and another group was treated with 2 µg/mL tunicamycin with or without pioglitazone for 48 hours.
Mice and treatment protocols
Male KK-Ay mice 8 weeks of age were obtained from Oriental Bio Laboratory (Seoul, Korea) and bred in standard conditions under a 12-hour light/dark cycle. All experiments using animals were performed in accordance with the Ethics Committee for Animal Experiments of the Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine. The experimental mice were placed on a high-fat (HF) diet (fat: 45% of energy content [39.4% from lard and 4.4 from soybean oil]; protein: 20% of energy content; and carbohydrate: 35% of energy content) or a HF diet containing 0.02% (wt/wt) pioglitazone for 6 weeks. Body weight and blood glucose levels were checked every week.
Protein isolation and immunoblotting
Cellular proteins were prepared by a RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA) with protease and phosphatase inhibitors. The concentration of protein was measured by the Bradford assay (Amersham Life Science, Arlington Height, IL, USA), and 20 µg of protein from each group was separated in 4% to 12% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) gels and transferred to polyvinylidene difluoride membranes. Proteins in the membranes were probed with primary antibodies for p-eIF2α (Ser51), IRE1α (14C10), CHOP (L63F7), phosphor-NF-κB p65 (S536), NF-κB, phosphor-stress-activated protein kinase (SAPK)/JNK (T183/Y185), SAPK/JNK, cleaved caspase-3 (D175), total caspase-3, β-actin (Cell Signaling Technology, Danvers, MA, USA), ATF6 (Abcam, Cambridge, MA, USA), and GRP78 (Santa Cruz Biotechnology) for 24 hours. The membranes were then exposed to secondary antibodies conjugated with horseradish peroxidase, and visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Rockford, IL, USA). ImageJ, a program for quantification, was used to measure the density of the scanned immunoblot bands. The density of phosphorylated NF-κB, SAPK/ JNK, and cleaved caspase-3 was normalized to the levels of NF-κB, SAPK/JNK, and caspase-3, respectively.
Immunofluorescence analysis
Pancreatic tissue samples were fixed with 4% paraformaldehyde for 24 hours and embedded within paraffin. Paraffin sections of 7 µm were dewaxed in xylene, and incubated with 0.5% hydrogen peroxide in methanol for 0.5 hours to block endogenous peroxidase activity. After washing with phosphate-buffered saline, tissue samples were blocked using normal goat serum for 0.5 hours, and then incubated with primary antibodies for insulin (Millipore, Billerica, MA, USA), glucagon, Glut2, monocyte chemoattractant protein-1 (MCP1), ATF6α, and GRP78 (Santa Cruz Biotechnology) for 24 hours. The tissue samples were then incubated with secondary antibodies conjugated with fluorescent dye (Thermo Fisher Scientific) for 1 hour. DAPI (4′,6-diamidino-2-phenylindole) solution (Invitrogen, Carlsbad, CA, USA) was used to visualize the nucleus, and fluorescent images were obtained using an Olympus BX52 microscope (Olympus Optical Co., Tokyo, Japan).
RNA isolation and real-time polymerase chain reaction analysis
At 60% to 70% confluence, total RNA was extracted using TRizol (Life Technologies, Carlsbad, CA, USA). After dose measurement, 2 µg of RNA was used to synthesize the first strand of cDNA using the RT enzyme Mix (Thermo Fisher Scientific), and it was amplified by SYBR green I Master (Roche Diagnostics, Indianapolis, IN, USA) and the following primers: TNFA, sense 5′-GTTCTATGGCCCAGACCCTCAC-3′ and antisense 5′-GGCACCACTAGTTGGTTGTCTTTG-3′ (NM-013693, 144 bp); IL6, sense 5′-CCACTTCACAAGTCGGAGGCTTA-3′ and antisense 5′-GCAAGTGCATCATCGTTGTTCATAC-3′ (NM-031168, 115 bp); IL1B, sense 5′-AGGTCATCACTATTG-GCAAC-3′ and antisense 5′-ACTCATCGTACTCCTGCTTG-3′ (NM-008361, 135 bp). Polymerase chain reaction (PCR) was performed in a Light Cycler 480 real-time PCR machine (Roche, Lewis, UK) with a pre-denaturation, denaturation, and annealing step, followed by additional 40 cycles and an extension step. The emission levels of green fluorescence by SYBR were detected and the relative expression levels of RNA were determined using the ΔΔCt method.
RESULTS
Pioglitazone attenuates palmitate-induced β-cell dysfunction and apoptosis
To study the role of pioglitazone in β-cells, MIN6 cells were incubated with palmitate and/or pioglitazone. Treatment with 0.5 mM palmitate significantly inhibited 25 mM glucose-stimulated insulin secretion (1% BSA vs. 500 µM palmitate/1% BSA, P<0.001), while insulin levels were significantly restored by pioglitazone treatment for 24 hours (500 µM palmitate/1% BSA vs. 10 nM pioglitazone/500 µM palmitate/1% BSA, P<0.001) (Fig. 1A) . Pioglitazone treatment also attenuated apoptosis, with a significant decrease of cleaved caspase-3 and PARP activity observed in MIN6 cells treated with high glucose and palmitate (Fig. 1B, C) .
Pioglitazone spontaneously improves the palmitateinduced inflammatory response and ER stress
As it has been reported that inflammation and ER stress are major causes of apoptosis and dysfunction in pancreatic β-cells www.e-enm.org 109 [16, 17] , we measured the inflammatory response and ER stress. To examine whether the protective effect of pioglitazone against free fatty acid-induced β-cell dysfunction was related to the inflammatory response and ER stress, we measured the expression of cytokines and proteins related to ER stress. The extreme increase in the expression of TNFA, IL6, and IL1B induced by palmitate was significantly ameliorated by co-treatment with pioglitazone (Fig. 1D) . Treatment with palmitate induced the expression of specific markers of the UPR pathways responding to ER stress, including p-eIF2α, GRP78, ATF6α, and CHOP, and the expression of these proteins was significantly reduced by pioglitazone treatment (Fig. 1E, F) . These results suggest that pioglitazone inhibits palmitate-induced inflammatory response and ER stress signaling, contributing to protection from β-cell dysfunction.
Pioglitazone represses the inflammatory response and ER stress in LPS-treated MIN6 cells
As shown in Fig. 1 , pioglitazone simultaneously repressed the palmitate-induced inflammatory response and reduced ER stress. Therefore, we evaluated the role of pioglitazone in MIN6 cells in which an inflammatory response or ER stress was induced. First, MIN6 cells were treated with 10 µg/mL LPS for 48 hours to induce an inflammatory response. In LPS-treated cells, increased phosphorylation of NF-κB and JNK was detected, and the expression of TNFA, IL6, and IL1B was elevated, meaning that LPS induced a major inflammatory response in the MIN6 cells. The induction of the inflammatory response by LPS also increased the expression of ER stress markers, such as p-eIF2α, GRP78, and CHOP. These data suggest that the inflammatory response could induce ER stress in MIN6 cells. Treatment with pioglitazone remarkably repressed the inflammatory response induced by LPS, with diminished phosphorylation of NF-κB and JNK, and reduced expression of the mRNA of inflammatory cytokines ( Fig. 2A-C) . Consistently, markers of ER stress were also significantly decreased by pioglitazone (Fig. 2D, E) . These data suggest that pioglitazone can repress the LPS-induced inflammatory response and ER stress in pancreatic β-cells.
Pioglitazone represses ER stress in tunicamycin-treated MIN6 cells
We next administered tunicamycin, an inducer of ER stress, to evaluate the effects of pioglitazone on the regulation of ER stress. Pioglitazone significantly repressed the expression of ER stress-related proteins, such as p-eIF2α, GRP78, cleaved-ATF6, and CHOP (Fig. 3A, B) . Treatment with tunicamycin resulted in a slight increase in the expression of TNFA and IL1B, but not IL6 (Fig. 3C) , while pioglitazone repressed only IL1B expression, indicating that the induction of the inflammatory response might be upstream of ER stress in β-cell dysfunction and that pioglitazone represses both the inflammatory response and ER stress in pancreatic β-cells.
Pioglitazone represses inflammation and ER stress in the pancreatic islet of diabetic mice
We next employed morphological investigations of pancreatic islet samples from KK-Ay mice, which were fed HF diets with or without pioglitazone, to explore the effects of pioglitazone on inflammation and ER stress. In the pancreas of HF-fed mice without pioglitazone, the expression of ATF6 and GRP78 was strongly detected in the islet, showing co-localization with insulin. However, the expression of ATF6 and GRP78 was remarkably decreased by pioglitazone, providing evidence that pioglitazone repressed ER stress in the pancreatic islets (Fig. 4A) . Treatment with pioglitazone also repressed the inflammatory response in the pancreatic islets, as a significant decrease of MCP1 was observed. Additionally, α-cell infiltration into the core of the pancreatic islet was decreased by pioglitazone (Fig.  4B) . In contrast, GLUT2, the main sensor of glucose in β-cells, was significantly increased by pioglitazone treatment (Fig. 4C) . These results indicated that pioglitazone treatment preserved β-cells against ER stress and the inflammatory response. Treat- 38 kDa Veh TU TU/Pio Pio ment with pioglitazone also attenuated the rise of blood glucose levels induced by the HF diet without altered body weight. In the 6th week, the blood glucose levels of the pioglitazone-treated mice were significantly lower than those in the HF group (254.50±3.33 mg/dL vs. 264.75±2.10 mg/dL, respectively). These data suggest that the preservation of pancreatic β-cell function by pioglitazone may play a meaningful role in the maintenance of blood glucose levels.
DISCUSSION
The use of PPARγ agonists to improve insulin resistance and prevent diabetes onset has been proposed in numerous studies using animal models and type 2 diabetes patients [18] [19] [20] . It has also been suggested that PPARγ agonist administration preserves islet mass in animal models, but this has been considered to be a systemic effect of PPARγ activation, not a direct effect on pancreatic β-cells. Despite the known importance of PPARγ expression [21] , its specific and direct role in β-cells is less well known. PPARγ, a nuclear receptor, is expressed in various tissues, including fat, muscle, and the liver, and is involved in the regulation of various genes contributing to glucose and lipid metabolism and insulin signaling [22] . Interestingly, the specific elimination of PPARG in pancreatic β-cells induced islet hyperplasia with increased replication on a chow diet [23] , indicating that PPARγ plays a direct role in β-cells. In this study, incubation with palmitate resulted in β-cell dysfunction and apoptosis, and simultaneously facilitated the expression of inflammatory cytokines and ER stress. Treatment with pioglitazone blocked all cellular toxicity; moreover, pioglitazone significantly attenuated the expression of inflammatory cytokines in LPS-treated β-cells. Lipotoxicity is known to be powerful inducer of inflammation and apoptosis [24] ; briefly, the accumulation of intracellular triglycerides results in increased levels of ceramide and facilitates NF-κB activation, thereby inducing apoptosis [25] . NF-κB is also activated by exposure to high glucose via the production of IL-1β or an increase in intracellular Ca 2+ [26, 27] . Moreover, the active form of NF-κB is transferred to the nucleus, and strongly stimulates the transcription of genes involved in the inflammatory response [28] , indicating that NF-κB is essential regulator of glucolipotoxicity, the inflammatory response, and apoptosis in toxicityinduced β-cells. In the present study, treatment with pioglitazone repressed LPS-induced NF-κB phosphorylation, and significantly and consistently decreased the expression of inflammatory cytokines ( Fig. 2A, B) , suggesting that NF-κB might be a key regulator of the repression of apoptosis and inflammation by pioglitazone in pancreatic β-cells.
In glucolipotoxicity-induced MIN6 cells and pancreatic islet samples from diabetic mice, pioglitazone significantly suppressed the expression of ER stress markers (Figs. 1, 4) . Moreover, the increase of ER stress markers by LPS and tunicamycin was also reversed by pioglitazone (Figs. 2, 3 ). These data suggest that PPARγ activation may play a direct role in the preservation of ER function and health in pancreatic β-cells. It was recently reported that sarco-ER Ca
2+
-ATPase (SERCA) 2, a regulator of the ER maintenance and secretion pathway, is also expressed in β-cells and modulated by PPARγ agonists. Moreover, the expression of SERCA2b was remarkably decreased by the inflammatory cytokine IL-1β in pancreatic islets [29] . The reduction of SERCA2b expression by inflammatory cytokines indirectly indicates that induction of the inflammatory response facilitates ER stress, as occurred in LPS induced β-cells (Fig. 2) . SERCA2 is also an essential regulator of the interaction between ER stress and insulin secretion, and the improvement of insulin secretion and ER stress by pioglitazone might be mediated by SERCA2 in pancreatic β-cells (Fig. 1) .
This study showed that PPARγ activation exerted a protective effect in pancreatic β-cells, mediated via repression of the inflammatory response and ER stress. PPARγ agonists might be used as a means not only to improve insulin resistance, but also to preserve β-cell survival and function.
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